Christian Weyer's most recent trade in Intercept Pharmaceuticals Inc was a trade of 46 Common Stock done at an average price of $24.3 . Disclosure was reported to the exchange on April 1, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals Inc | Christian Weyer | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 01 Apr 2021 | 46 | 27,341 (0%) | 0% | 24.3 | 1,117 | Common Stock |
| Intercept Pharmaceuticals Inc | Christian Weyer | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.66 per share. | 27 Feb 2021 | 357 | 27,387 (0%) | 0% | 21.7 | 7,733 | Common Stock |
| Intercept Pharmaceuticals Inc | Christian Weyer | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 19,700 | 19,700 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Christian Weyer | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 12,600 | 27,744 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Christian Weyer | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.27 per share. | 27 Nov 2020 | 357 | 15,977 (0%) | 0% | 37.3 | 13,305 | Common Stock |
| Intercept Pharmaceuticals Inc | Christian Weyer | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.09 per share. | 01 Oct 2020 | 46 | 16,334 (0%) | 0% | 42.1 | 1,936 | Common Stock |